Pfizer Inc and Biohaven Pharmaceutical Holding Company Ltd announced on 27th April that the European Commission (EC) has granted marketing authorisation for VYDURA® (rimegepant), a calcitonin gene-related peptide (CGRP) receptor antagonist for both the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine in adults who have at least four migraine attacks…
Category: Headache
Teva launches pre-filled pen for anti-CGRP migraine therapy AJOVY®▼ (fremanezumab) in the UK
On 21st July 2020, Teva UK Limited announced that a pre-filled pen for AJOVY® (fremanezumab) injection is now available, which will give patients on AJOVY® added convenience and flexibility not previously available with the AJOVY® pre-filled syringe. Indicated for the prevention of migraine in adults who have at least 4 migraine days per month, AJOVY®…
